- Home
- KROS vs MUJ Comparison
KROS vs MUJ Comparison
Compare KROS & MUJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- MUJ
- Stock Information
- Founded
- KROS 2015
- MUJ 1998
- Country
- KROS United States
- MUJ United States
- Employees
- KROS N/A
- MUJ N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- MUJ Investment Bankers/Brokers/Service
- Sector
- KROS Health Care
- MUJ Finance
- Exchange
- KROS Nasdaq
- MUJ Nasdaq
- Market Cap
- KROS 565.0M
- MUJ 619.6M
- IPO Year
- KROS 2020
- MUJ N/A
- Fundamental
- Price
- KROS $15.91
- MUJ $11.66
- Analyst Decision
- KROS Buy
- MUJ
- Analyst Count
- KROS 14
- MUJ 0
- Target Price
- KROS $20.56
- MUJ N/A
- AVG Volume (30 Days)
- KROS 424.2K
- MUJ 108.0K
- Earning Date
- KROS 11-05-2025
- MUJ 01-01-0001
- Dividend Yield
- KROS N/A
- MUJ 4.36%
- EPS Growth
- KROS N/A
- MUJ N/A
- EPS
- KROS 0.47
- MUJ N/A
- Revenue
- KROS $232,844,000.00
- MUJ N/A
- Revenue This Year
- KROS $6,657.47
- MUJ N/A
- Revenue Next Year
- KROS N/A
- MUJ N/A
- P/E Ratio
- KROS $34.14
- MUJ N/A
- Revenue Growth
- KROS 85820.30
- MUJ N/A
- 52 Week Low
- KROS $9.12
- MUJ $9.74
- 52 Week High
- KROS $72.37
- MUJ $11.70
- Technical
- Relative Strength Index (RSI)
- KROS 54.08
- MUJ 67.60
- Support Level
- KROS $15.50
- MUJ $11.51
- Resistance Level
- KROS $16.44
- MUJ $11.49
- Average True Range (ATR)
- KROS 0.57
- MUJ 0.11
- MACD
- KROS -0.01
- MUJ -0.01
- Stochastic Oscillator
- KROS 59.87
- MUJ 89.74
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.